Palantir's AI Powers Nebraska Medicine: Inks Multi-Million Dollar Deal To Advance Patient Care Palantir Technologies Inc. (NYSE:PLTR) shares are trading higher premarket Tuesday. The company inked a multi-year, multi-million-dollar contract with Nebraska Medicine. As per the deal, Palantir will utilize its Artificial Intelligence Platform (AIP) to enhance healthcare through transformative technologies. Palantir and Nebraska Medicine began their collaboration in January 2024, with a shared mission to quickly address critical healthcare challenges. Palantir plans to continue its partnership, aiding Nebraska Medicine by providing AI software for patient flow, nurse allocation, clinical supplies, and revenue cycle optimization. The partnership will also expand Nebraska’s Foundry Ontology and explore new opportunities in clinical research and care to improve patient outcomes. Drew Goldstein, Co-Head of Healthcare at Palantir, stated, “Their swift commitment to this enterprise partnership highlights our shared focus on rapidly delivering value and driving impactful outcomes to enhance patient care.” Also Read: Palantir CEO Offers ‘Radical’ Take On National Security: ‘Touch An American And We’ll Inflict Pain On You For Generations’ Michael Ash, Nebraska Medicine president and chief operating officer, said, “The technology allows our staff to work smarter, and for more of our patients to leave the hospital as soon as they’re able. Most exciting for us – this is just the beginning of the innovations we’ll discover together and lead the way for other hospitals.” Last month, Palantir disclosed that it was named a leader in artificial intelligence (AI) and machine learning (ML) platforms. Also, Palantir recently announced a strategic partnership with Sompo to enhance AI-driven solutions. Investors can gain exposure to the stock via REX AI Equity Premium Income ETF (NASDAQ:AIPI) and Spinnaker ETF Series Tuttle Capital Self Defense Index ETF (BATS:GUNZ). Price Action: PLTR shares are up 2.2% at $37.11 premarket at the last check Tuesday. Photo via Shutterstock Read Next: Palantir ‘Key Enabler’ Of Clients’ Businesses, Says Bullish Analyst, As CEO Alex Karp Touts 10-Fold Growth From Current Levels UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? PALANTIR TECHNOLOGIES (PLTR): Free Stock Analysis Report This article Palantir's AI Powers Nebraska Medicine: Inks Multi-Million Dollar Deal To Advance Patient Care originally appeared on Benzinga.com © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Palantir's AI Powers Nebraska Medicine: Inks Multi-Million Dollar Deal To Advance Patient Care
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research.
Start Your Free Trial Now!Not sure where to invest today?
Kalkine’s latest research highlights three companies identified through in-depth analysis and market insights.
Explore these research reports to learn about companies currently being tracked by our analysts and make more informed investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...